Safety of Remdesivir and Tocilizumab in COVID-19 Treatment
https://doi.org/10.30895/2312-7821-2020-8-3-160-162
Abstract
An important part of treating patients infected with SARS-CoV-2 is to ensure effective pathogenetic and symptomatic therapy before life-threatening complications, such as pneumonia, acute respiratory distress syndrome, or sepsis begin to develop. Current COVID-19 treatment protocols often use remdesivir and tocilizumab, though safety data on these drugs are insufficient. Therefore, experts of the Centre for Evaluation of Medicinal Products’ Safety of the Federal State Budgetary Institution “Scientific Centre for Expert Evaluation of Medicinal Products” of the Ministry of Health of the Russian Federation studied adverse reactions to remdesivir and tocilizumab, which are registered in the VigiBase (as of August 27, 2020), the global database of individual case safety reports.
About the Authors
Alexandra A. Taube
Scientific Centre for Expert Evaluation of Medicinal Products, Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
Cand. Sci. (Pharm.).
8/2 Petrovsky Blvd, Moscow 127051
Alexandr S. Kazakov
Scientific Centre for Expert Evaluation of Medicinal Products, Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
Cand. Sci. (Med.).
8/2 Petrovsky Blvd, Moscow 127051
Marya A. Darmostukova
Scientific Centre for Expert Evaluation of Medicinal Products, Peoples’ Friendship University of Russia
Russian Federation
8/2 Petrovsky Blvd, Moscow 127051
Russian Federation
8/2 Petrovsky Blvd, Moscow 127051
Natalya Yu. Velts
Scientific Centre for Expert Evaluation of Medicinal Products, Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
Cand. Sci. (Pharm.), Associate Professor
8/2 Petrovsky Blvd, Moscow 127051
Elena V. Shubnikova
Scientific Centre for Expert Evaluation of Medicinal Products, Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
Cand. Sci. (Med.).
8/2 Petrovsky Blvd, Moscow 127051
Renad N. Alyautdin
Scientific Centre for Expert Evaluation of Medicinal Products, Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
Dr. Sci. (Med.), Professor
8/2 Petrovsky Blvd, Moscow 127051
References
1. Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2(8):e474–e484. https://doi.org/10.1016/S2665-9913(20)30173-9
2. Favalli EG, Caporali R. GM-CSF in the treatment of COVID-19: a new conductor in the pathogenesis of cytokine storm? Lancet Rheumatol. 2020;2(8):e448–e449. https://doi.org/10.1016/S2665-9913(20)30185-5
3. Fu B, Xu X, Wei H. Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med. 2020;18(1):164. https://doi.org/10.1186/s12967-020-02339-3
4. Singh AK, Singh A, Singh R, Misra A. Remdesivir in COVID-19: a critical review of pharmacology, pre-clinical and clinical studies. Diabetes Metab Syndr. 2020;14(4):641–8. https://doi.org/10.1016/j.dsx.2020.05.018
5. Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222. https://doi.org/10.1038/s41467-019-13940-6
6. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 – preliminary report. N Engl J Med. 2020;383:10.1056/NEJMc2022236#sa5. https://doi.org/10.1056/NEJMc2022236
7. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, at al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–78. https://doi.org/10.1016/S0140-6736(20)31022-9
8. Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9(2):e00221-18. https://doi.org/10.1128/mBio.00221-18
9. Pardo J, Shukla AM, Chamarthi G, Gupte A. The journey of remdesivir: from Ebola to COVID-19. Drugs Context. 2020;9:2020-4-14. https://doi.org/10.7573/dic.2020-4-14
10. Bimonte S, Crispo A, Amore A, Celentano E, Cuomo A, Cascella M. Potential antiviral drugs for SARS-Cov-2 treatment: preclinical findings and ongoing clinical research. In Vivo. 2020;34(3 Suppl):1597–1602. https://doi.org/10.21873/invivo.11949
11. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117(20):10970–5. https://doi.org/10.1073/pnas.2005615117
12. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020;55(5):105954. https://doi.org/10.1016/j.ijantimicag.2020.105954
13. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3
Review
For citations:
Safety of Remdesivir and Tocilizumab in COVID-19 Treatment. Safety and Risk of Pharmacotherapy. 2020;8(3):160-162. (In Russ.) https://doi.org/10.30895/2312-7821-2020-8-3-160-162
Views:
3629
Email this article 